Correction: Loss of EGFR signaling-regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance [Oncotarget. 5, (2014), 3770-3784]doi 10.18632/oncotarget.1994

Man Kit Siu, Wassim Abou-Kheir, Juan Juan Yin, Yung Sheng Chang, Ben Barrett, Florent Suau, Orla Casey, Wei Yu Chen, Lei Fang, Paul Hynes, Yao Yu Hsieh, Yen Nien Liu, Jiaoti Huang, Kathleen Kelly

研究成果: 雜誌貢獻評論/辯論

2 引文 (Scopus)

摘要

This article has been corrected: The author affiliation is given below: Yao-Yu Hsieh1,6,9 9 Department of Internal Medicine, Division of Hematology and Oncology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
原文英語
頁(從 - 到)32403
頁數1
期刊Oncotarget
9
發行號64
DOIs
出版狀態已發佈 - 八月 17 2018

指紋

Bone Neoplasms
Protein-Tyrosine Kinases
Prostatic Neoplasms
Medicine
Neoplasm Metastasis
Hematology
Internal Medicine
Taiwan

ASJC Scopus subject areas

  • Oncology

引用此文

Correction : Loss of EGFR signaling-regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance [Oncotarget. 5, (2014), 3770-3784]doi 10.18632/oncotarget.1994. / Siu, Man Kit; Abou-Kheir, Wassim; Yin, Juan Juan; Chang, Yung Sheng; Barrett, Ben; Suau, Florent; Casey, Orla; Chen, Wei Yu; Fang, Lei; Hynes, Paul; Hsieh, Yao Yu; Liu, Yen Nien; Huang, Jiaoti; Kelly, Kathleen.

於: Oncotarget, 卷 9, 編號 64, 17.08.2018, p. 32403.

研究成果: 雜誌貢獻評論/辯論

Siu, Man Kit ; Abou-Kheir, Wassim ; Yin, Juan Juan ; Chang, Yung Sheng ; Barrett, Ben ; Suau, Florent ; Casey, Orla ; Chen, Wei Yu ; Fang, Lei ; Hynes, Paul ; Hsieh, Yao Yu ; Liu, Yen Nien ; Huang, Jiaoti ; Kelly, Kathleen. / Correction : Loss of EGFR signaling-regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance [Oncotarget. 5, (2014), 3770-3784]doi 10.18632/oncotarget.1994. 於: Oncotarget. 2018 ; 卷 9, 編號 64. 頁 32403.
@article{79bfee96310947239f191b500b85ea0b,
title = "Correction: Loss of EGFR signaling-regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance [Oncotarget. 5, (2014), 3770-3784]doi 10.18632/oncotarget.1994",
abstract = "This article has been corrected: The author affiliation is given below: Yao-Yu Hsieh1,6,9 9 Department of Internal Medicine, Division of Hematology and Oncology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.",
author = "Siu, {Man Kit} and Wassim Abou-Kheir and Yin, {Juan Juan} and Chang, {Yung Sheng} and Ben Barrett and Florent Suau and Orla Casey and Chen, {Wei Yu} and Lei Fang and Paul Hynes and Hsieh, {Yao Yu} and Liu, {Yen Nien} and Jiaoti Huang and Kathleen Kelly",
year = "2018",
month = "8",
day = "17",
doi = "10.18632/oncotarget.26020",
language = "English",
volume = "9",
pages = "32403",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "64",

}

TY - JOUR

T1 - Correction

T2 - Loss of EGFR signaling-regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance [Oncotarget. 5, (2014), 3770-3784]doi 10.18632/oncotarget.1994

AU - Siu, Man Kit

AU - Abou-Kheir, Wassim

AU - Yin, Juan Juan

AU - Chang, Yung Sheng

AU - Barrett, Ben

AU - Suau, Florent

AU - Casey, Orla

AU - Chen, Wei Yu

AU - Fang, Lei

AU - Hynes, Paul

AU - Hsieh, Yao Yu

AU - Liu, Yen Nien

AU - Huang, Jiaoti

AU - Kelly, Kathleen

PY - 2018/8/17

Y1 - 2018/8/17

N2 - This article has been corrected: The author affiliation is given below: Yao-Yu Hsieh1,6,9 9 Department of Internal Medicine, Division of Hematology and Oncology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.

AB - This article has been corrected: The author affiliation is given below: Yao-Yu Hsieh1,6,9 9 Department of Internal Medicine, Division of Hematology and Oncology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.

UR - http://www.scopus.com/inward/record.url?scp=85051835232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051835232&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.26020

DO - 10.18632/oncotarget.26020

M3 - Comment/debate

AN - SCOPUS:85051835232

VL - 9

SP - 32403

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 64

ER -